Sirona Biochem Corp.

Equities

SBM

CA82967M1005

Biotechnology & Medical Research

Delayed Toronto S.E. 03:59:59 2024-04-22 pm EDT 5-day change 1st Jan Change
0.065 CAD +8.33% Intraday chart for Sirona Biochem Corp. 0.00% -45.83%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Sirona Biochem Provides Update on Anti-Aging Product MT
Sirona Biochem Corp. announced that it has received CAD 0.1325 million in funding CI
Sirona Biochem Corp. Reports Earnings Results for the First Quarter Ended January 31, 2024 CI
Sirona Biochem Receives Commercial-Grade GlycoProteMim Based Anti-Aging Serum Formulations MT
Sirona Biochem Corp. Reports Earnings Results for the Full Year Ended October 31, 2023 CI
Sirona Biochem Corp. Announces Loan in the Aggregate Principal Amount of Up to $1,000,000 CI
Sirona Biochem Initiated Private Placement MT
Sirona Biochem Corp. announced that it expects to receive CAD 1 million in funding CI
Sirona Biochem Corp. announced that it expects to receive CAD 1 million in funding CI
Sirona Biochem Corrects Earlier Statement MT
Sirona Biochem Provides Corporate Update MT
Sirona Biochem Launches Cosmetics Subsidiary MT
Sirona Biochem Corp. Introduces A Wholly-Owned Subsidiary Sirona Laboratories CI
Sirona Biochem Initiates GlycoProteMim Trademark for Anti-Aging Molecule TFC-1326 MT
Sirona Biochem Corp. Initiates GlycoProteMim?? Trademark for Anti-Aging Molecule TFC-1326 CI
Sirona Biochem Corp. Announces the Results of Its Research Collaboration with the International Centre for Genetic Engineering and Biotechnology in Advancing Sirona's Antiviral Compound Library CI
Sirona Biochem Announced Payment of Convertible Debenture Interests in Shares MT
Sirona Biochem Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2023 CI
Sirona Biochem Provides Strategic Review Update MT
Sirona Biochem Corp. Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2023 CI
Sirona Biochem Advances Antiviral Research with New Compound Candidates for Testing At the ICGEB CI
Sirona Biochem to Present Anti-Aging Technology at BIO 2023 Conference in Boston MT
Sirona Biochem Announces Exceptional Clinical Trial Results for Anti-Aging Compound TFC-1326 CI
Sirona Biochem Raises C$1.56 Million from a Private Placement of Convertible-Debenture Units MT
Sirona Biochem Corp. announced that it has received CAD 1.563 million in funding CI
Chart Sirona Biochem Corp.
More charts
Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with proprietary platform developed at its laboratory facility in France. Through its wholly owned subsidiary TFChem S.A.R.L., the Company specializes in stabilizing carbohydrate molecules. The principal activities of the Company include development of cosmetic and pharmaceutical active ingredients. TFChem develops and markets its GlycoMim technology for pharmaceutical and biotechnology comp anies. TFChem’s proprietary chemistry technology can be applied to the development of several pharmaceutical domains such as cancer, diabetes, pain and inflammation and cardio-vascular diseases. Its cosmetic therapeutic area includes skincare-dark spot corrector (Rx & OTC), cell preservation and repair (including keloid and scar therapy), skincare-anti aging/anti-wrinkle and skincare-cellulite treatment. It has developed an active ingredient, TFC-1067 for the treatment of Dyschromia (Dark spots on the skin).
More about the company
  1. Stock Market
  2. Equities
  3. SBM Stock
  4. News Sirona Biochem Corp.
  5. Sirona Biochem Says to Start Clinical Trial of Anti-Aging Compound, Testing of Antivirals in Second Half of 2022